STAT+: Pharmalittle: We’re reading about GLP-1s becoming lifestyle drugs, a setback for Merck and Daiichi, and more

STAT reports that GLP-1 drugs, once promoted as tools to address obesity as a medical issue, are increasingly being seen and marketed as a way to look and feel better generally. Novo Nordisk, the field’s pioneer, has leaned into that shift.

The change is no accident: early Novo Nordisk and Eli Lilly marketing was designed to convince payers and society that obesity was a disease needing treatment. But after seeing expansion of insurance coverage stall due to the drugs’ high price and usage, the companies began selling their products directly to patients.

Separately, Merck and Daiichi Sankyo withdrew their U.S. application seeking accelerated approval for an experimental lung cancer therapy, marking the second pullback under their multibillion-dollar cancer alliance, Reuters notes. The decision followed discussions with the FDA, which determined that data from a mid-stage clinical study did not satisfy requirements needed to support an early green light. The therapy was under review to treat adults with aggressive, extensive-stage small cell lung cancer, and last year the companies pulled the application for another lung cancer candidate after it failed to extend patients’ lives in a late-stage study.

Together, the items illustrate two pharma industry dynamics: GLP-1 makers are pivoting toward direct-to-patient lifestyle positioning as insurer coverage stalls, while oncology partnerships face regulatory delays when mid-stage data fall short of accelerated approval standards.